Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Accumulated Expenses (2020 - 2026)

Bioventus filings provide 6 years of Other Accumulated Expenses readings, the most recent being $4.2 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 7.48% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 7.48% increase, with the full-year FY2025 number at $4.2 million, up 7.48% from a year prior.
  • Other Accumulated Expenses hit $4.2 million in Q4 2025 for Bioventus, down from $4.4 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $10.2 million in Q2 2021 to a low of $3.0 million in Q4 2021.
  • Median Other Accumulated Expenses over the past 5 years was $4.1 million (2021), compared with a mean of $4.4 million.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 61.36% in 2022 and later soared 35.38% in 2023.
  • Bioventus' Other Accumulated Expenses stood at $3.6 million in 2021, then grew by 1.38% to $3.6 million in 2022, then skyrocketed by 33.52% to $4.8 million in 2023, then decreased by 18.67% to $3.9 million in 2024, then grew by 7.48% to $4.2 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $4.2 million (Q4 2025), $4.4 million (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.